OKYO Pharma to Ring the Opening Bell at Nasdaq

Core Viewpoint - OKYO Pharma Limited is celebrating its advancements in developing urcosimod for treating neuropathic corneal pain (NCP) by ringing the Opening Bell at Nasdaq, highlighting its commitment to addressing unmet medical needs in ocular pain [1][3]. Company Overview - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on innovative therapies for neuropathic corneal pain, with its shares traded on the NASDAQ Capital Market [6]. - The company is advancing its pipeline, having recently completed a successful Phase 2 trial of urcosimod in patients with NCP and is planning a larger multicenter trial set to begin in Q1 2026 [6]. Product Information - Urcosimod, previously known as OK-101, is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 G-protein-coupled receptor, which is involved in the inflammatory response and pain reduction [5]. - Positive results from a Phase 2 trial demonstrated significant pain reduction in NCP patients, with urcosimod showing statistical significance across multiple endpoints [5]. Industry Context - Neuropathic corneal pain (NCP) is characterized by severe pain and sensitivity in the eyes, face, or head, often resulting from nerve damage and inflammation, with no FDA-approved therapies currently available [4]. - Existing treatments for NCP are limited and often off-label, indicating a significant unmet medical need in this area [4].